[go: up one dir, main page]

MX2010005960A - Biomarcadores de braf. - Google Patents

Biomarcadores de braf.

Info

Publication number
MX2010005960A
MX2010005960A MX2010005960A MX2010005960A MX2010005960A MX 2010005960 A MX2010005960 A MX 2010005960A MX 2010005960 A MX2010005960 A MX 2010005960A MX 2010005960 A MX2010005960 A MX 2010005960A MX 2010005960 A MX2010005960 A MX 2010005960A
Authority
MX
Mexico
Prior art keywords
braf
biomarkers
disease
methods
erk2
Prior art date
Application number
MX2010005960A
Other languages
English (en)
Inventor
William T Windsor
Jason S Simon
Thomas J Hosted
Lorenzo Marc M De
Donna Marie Carr
Ahmed A Samatar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010005960A publication Critical patent/MX2010005960A/es

Links

Classifications

    • G01N33/5758—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención provee, entre otras cosas, métodos para predecir la sensibilidad de una enfermedad, tal como cáncer, a un inhibidor de ERK1 o ERK2 o MEK detectando la presencia de un alelo de BRAF en células que median la enfermedad; se proveen también métodos de tratamiento.
MX2010005960A 2007-11-30 2008-11-26 Biomarcadores de braf. MX2010005960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99135107P 2007-11-30 2007-11-30
US3461508P 2008-03-07 2008-03-07
PCT/US2008/084858 WO2009073513A1 (en) 2007-11-30 2008-11-26 Braf biomarkers

Publications (1)

Publication Number Publication Date
MX2010005960A true MX2010005960A (es) 2010-06-11

Family

ID=40521987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005960A MX2010005960A (es) 2007-11-30 2008-11-26 Biomarcadores de braf.

Country Status (6)

Country Link
US (1) US20110158944A1 (es)
EP (1) EP2220503A1 (es)
JP (3) JP5603777B2 (es)
CA (1) CA2706453A1 (es)
MX (1) MX2010005960A (es)
WO (1) WO2009073513A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010005960A (es) * 2007-11-30 2010-06-11 Schering Corp Biomarcadores de braf.
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
US9766249B2 (en) * 2010-04-19 2017-09-19 Biomarker Strategies, Llc Compositions and methods for prediction of drug sensitivity, resistance, and disease progression
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center METHOD FOR THE TREATMENT OF MELANOMA
EP2508184A1 (en) 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
AU2012253525B2 (en) * 2011-05-10 2016-09-22 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
JP6153758B2 (ja) * 2012-04-20 2017-06-28 アークレイ株式会社 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット
US10077474B2 (en) 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
WO2014168801A2 (en) * 2013-04-08 2014-10-16 Merck Sharp & Dohme Corp. Methods and compositions for treating cancer
AU2014315142B2 (en) * 2013-09-05 2020-07-02 Memorial Sloan-Kettering Cancer Center DDX43 as a biomarker of resistance to MEK1/2 inhibitors
US9694033B2 (en) 2014-01-24 2017-07-04 The Cleveland Clinic Foundation IL-9 secreting CD8+ Tc9 cells and methods of treating cancer
US11186874B2 (en) 2014-06-13 2021-11-30 Dana-Farber Cancer Institute, Inc. ERK1 and ERK2 mutations that confer resistance to MAPK pathway inhibitors
US11542240B2 (en) 2018-12-20 2023-01-03 Trustees Of Boston University STK19 inhibitors for treatment of cancer
US11879010B2 (en) 2021-09-30 2024-01-23 The Charlotte Mecklenburg Hospital Authority Methods and compositions for pretargeted immunotherapy
WO2023190967A1 (ja) * 2022-03-31 2023-10-05 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
AU2006326616B2 (en) * 2005-12-13 2012-09-06 Merck Sharp & Dohme Llc Polycyclic indazole derivatives that are ERK inhibitors
WO2007097937A1 (en) * 2006-02-16 2007-08-30 Schering Corporation Pyrrolidine derivatives as erk inhibitors
US7951819B2 (en) * 2006-04-26 2011-05-31 Cancer Research Technology Limited Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
MX2010005960A (es) * 2007-11-30 2010-06-11 Schering Corp Biomarcadores de braf.

Also Published As

Publication number Publication date
JP2011507490A (ja) 2011-03-10
WO2009073513A1 (en) 2009-06-11
JP5603777B2 (ja) 2014-10-08
JP2013031455A (ja) 2013-02-14
JP2014221063A (ja) 2014-11-27
US20110158944A1 (en) 2011-06-30
EP2220503A1 (en) 2010-08-25
CA2706453A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
MX2010005960A (es) Biomarcadores de braf.
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
BRPI1011934A8 (pt) Composição
UY32698A (es) Marcadores de riesgo para enfermedades cardiovasculares
MX370249B (es) Deteccion de aberraciones genéticas o moleculares asociadas con el cáncer.
NI201400078A (es) Derivados de lactamas útiles como inhibidores mutantes de idh1
CO6561839A2 (es) Alteracion genómica dirigida
IT1395716B1 (it) Cuscinetto, meccanismo di fissaggio e metodo per fissare almeno un pattino.
MX350533B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
MX2013014153A (es) Biomarcadores paa terapia de inhibidor de hedgehog.
EP2368221A4 (en) FINANCIAL GADGETS
UY30371A1 (es) Compuestos quimicos
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
NO345047B1 (no) Anode for elektrokjemiske prosesser
CL2009001363S1 (es) Pieza para maquina de afeitar.
BR122020012978A8 (pt) Método de quantificação de um produto específico em uma reação de amplificação por corte e extensão (near)
SG10201407036YA (en) Markers of Endothelial Progenitor Cells and Uses Thereof
MX2015010740A (es) Tratamiento del cancer basado en el estratificacion de anhidrasa carbonica ix (caix).
BRPI0906090A2 (pt) substrato para análise de uma enzima, molécula e método para detectar atividade enzimática .
ATE525484T1 (de) Slco1b3-genotyp
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
CL2012002762A1 (es) Método para pronosticar el riesgo de recurrencia de cáncer de próstata en un sujeto, que comprende determinar los niveles de expresión de por lo menos dos marcadores y la probabilidad predictiva en base a un nomograma de kattan; dispositivos; y kit.
MX2021009987A (es) Metodos para el etiquetado de celulas eucariotas de un organismo multicelular utilizando compuestos monosacaridos modificados.
WO2011044513A9 (en) Diagnostic and prognostic markers for cancer

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MOTOROLA MOBILITY, INC.

FG Grant or registration